Clinical Trials Logo

Cannabinoid Hyperemesis Syndrome clinical trials

View clinical trials related to Cannabinoid Hyperemesis Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05812339 Enrolling by invitation - Gastroparesis Clinical Trials

Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls

Start date: November 1, 2022
Phase:
Study type: Observational

This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and correlation of metrics with patient symptoms among healthy adults and patients diagnosed with upper abdominal motility disorders. GAS is intended to record, store, view and process gastric myoelectrical activity. This is a proprietary system consisting of multiple electrodes arranged on an array that is placed precisely over the stomach, a reader to collect the electrode measurements and a smart tablet application to track patient reported symptoms. Participants meeting inclusion and exclusion criteria will continue fasting for 30 minutes after the Gastric Alimetry System has been applied and begun measuring, eat a standard study meal within 10 minutes and remain quietly seated, reclining, for 4 hours as the GAS continues to collect data. The array is removed and the abdomen is examined for evidence of skin effects.

NCT ID: NCT04283292 Recruiting - Clinical trials for Cannabinoid Hyperemesis Syndrome

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

Start date: December 1, 2020
Phase: Phase 4
Study type: Interventional

This study aims to determine if capsaicin cream offers symptomatic relief to patients suffering from Cannabinoid Hyperemesis Syndrome (condition that leads to repeated and severe bouts of vomiting).